COVID-19 Is a Multi-Organ Aggressor: Epigenetic and Clinical Marks

Mankgopo Magdeline Kgatle; Ismaheel Opeyemi Lawal; Gabriel Mashabela; Tebatso Moshoeu Gillian Boshomane; Palesa Caroline Koatale; Phetole Walter Mahasha; Honest Ndlovu; Mariza Vorster; Hosana Gomes Rodrigues; Jan Rijn Zeevaart; Siamon Gordon; Pedro Moura-Alves; Mike Machaba Sathekge

doi:10.3389/fimmu.2021.752380

COVID-19 Is a Multi-Organ Aggressor: Epigenetic and Clinical Marks

Mankgopo Magdeline Kgatle^*
, Ismaheel Opeyemi Lawal
, Gabriel Mashabela
, Tebatso Moshoeu Gillian Boshomane
, Palesa Caroline Koatale
, Phetole Walter Mahasha
, Honest Ndlovu
, Mariza Vorster
, Hosana Gomes Rodrigues
, Jan Rijn Zeevaart
, Siamon Gordon
, Pedro Moura-Alves
, Mike Machaba Sathekge^*

^*Corresponding author for this work

Graduate Institute of Biomedical Sciences

Research output: Contribution to journal › Review article › peer-review

33 Scopus citations

Abstract

The progression of coronavirus disease 2019 (COVID-19), resulting from a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, may be influenced by both genetic and environmental factors. Several viruses hijack the host genome machinery for their own advantage and survival, and similar phenomena might occur upon SARS-CoV-2 infection. Severe cases of COVID-19 may be driven by metabolic and epigenetic driven mechanisms, including DNA methylation and histone/chromatin alterations. These epigenetic phenomena may respond to enhanced viral replication and mediate persistent long-term infection and clinical phenotypes associated with severe COVID-19 cases and fatalities. Understanding the epigenetic events involved, and their clinical significance, may provide novel insights valuable for the therapeutic control and management of the COVID-19 pandemic. This review highlights different epigenetic marks potentially associated with COVID-19 development, clinical manifestation, and progression.

Original language	English
Article number	752380
Journal	Frontiers in Immunology
Volume	12
DOIs	https://doi.org/10.3389/fimmu.2021.752380
State	Published - 08 10 2021

Bibliographical note

Publisher Copyright:
© Copyright © 2021 Kgatle, Lawal, Mashabela, Boshomane, Koatale, Mahasha, Ndlovu, Vorster, Rodrigues, Zeevaart, Gordon, Moura-Alves and Sathekge.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

ACE2
COVID-19
SARS-CoV-2
TMPRSS2
cytokine storm
epigenetics
multi-organ
pro-inflammatory cytokines

Access to Document

10.3389/fimmu.2021.752380

Cite this

@article{71d232afa0e44df584ed9b980ab29232,

title = "COVID-19 Is a Multi-Organ Aggressor: Epigenetic and Clinical Marks",

abstract = "The progression of coronavirus disease 2019 (COVID-19), resulting from a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, may be influenced by both genetic and environmental factors. Several viruses hijack the host genome machinery for their own advantage and survival, and similar phenomena might occur upon SARS-CoV-2 infection. Severe cases of COVID-19 may be driven by metabolic and epigenetic driven mechanisms, including DNA methylation and histone/chromatin alterations. These epigenetic phenomena may respond to enhanced viral replication and mediate persistent long-term infection and clinical phenotypes associated with severe COVID-19 cases and fatalities. Understanding the epigenetic events involved, and their clinical significance, may provide novel insights valuable for the therapeutic control and management of the COVID-19 pandemic. This review highlights different epigenetic marks potentially associated with COVID-19 development, clinical manifestation, and progression.",

keywords = "ACE2, COVID-19, SARS-CoV-2, TMPRSS2, cytokine storm, epigenetics, multi-organ, pro-inflammatory cytokines",

author = "Kgatle, \{Mankgopo Magdeline\} and Lawal, \{Ismaheel Opeyemi\} and Gabriel Mashabela and Boshomane, \{Tebatso Moshoeu Gillian\} and Koatale, \{Palesa Caroline\} and Mahasha, \{Phetole Walter\} and Honest Ndlovu and Mariza Vorster and Rodrigues, \{Hosana Gomes\} and Zeevaart, \{Jan Rijn\} and Siamon Gordon and Pedro Moura-Alves and Sathekge, \{Mike Machaba\}",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2021 Kgatle, Lawal, Mashabela, Boshomane, Koatale, Mahasha, Ndlovu, Vorster, Rodrigues, Zeevaart, Gordon, Moura-Alves and Sathekge.",

year = "2021",

month = oct,

day = "8",

doi = "10.3389/fimmu.2021.752380",

language = "英语",

volume = "12",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - COVID-19 Is a Multi-Organ Aggressor

T2 - Epigenetic and Clinical Marks

AU - Kgatle, Mankgopo Magdeline

AU - Lawal, Ismaheel Opeyemi

AU - Mashabela, Gabriel

AU - Boshomane, Tebatso Moshoeu Gillian

AU - Koatale, Palesa Caroline

AU - Mahasha, Phetole Walter

AU - Ndlovu, Honest

AU - Vorster, Mariza

AU - Rodrigues, Hosana Gomes

AU - Zeevaart, Jan Rijn

AU - Gordon, Siamon

AU - Moura-Alves, Pedro

AU - Sathekge, Mike Machaba

PY - 2021/10/8

Y1 - 2021/10/8

N2 - The progression of coronavirus disease 2019 (COVID-19), resulting from a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, may be influenced by both genetic and environmental factors. Several viruses hijack the host genome machinery for their own advantage and survival, and similar phenomena might occur upon SARS-CoV-2 infection. Severe cases of COVID-19 may be driven by metabolic and epigenetic driven mechanisms, including DNA methylation and histone/chromatin alterations. These epigenetic phenomena may respond to enhanced viral replication and mediate persistent long-term infection and clinical phenotypes associated with severe COVID-19 cases and fatalities. Understanding the epigenetic events involved, and their clinical significance, may provide novel insights valuable for the therapeutic control and management of the COVID-19 pandemic. This review highlights different epigenetic marks potentially associated with COVID-19 development, clinical manifestation, and progression.

AB - The progression of coronavirus disease 2019 (COVID-19), resulting from a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, may be influenced by both genetic and environmental factors. Several viruses hijack the host genome machinery for their own advantage and survival, and similar phenomena might occur upon SARS-CoV-2 infection. Severe cases of COVID-19 may be driven by metabolic and epigenetic driven mechanisms, including DNA methylation and histone/chromatin alterations. These epigenetic phenomena may respond to enhanced viral replication and mediate persistent long-term infection and clinical phenotypes associated with severe COVID-19 cases and fatalities. Understanding the epigenetic events involved, and their clinical significance, may provide novel insights valuable for the therapeutic control and management of the COVID-19 pandemic. This review highlights different epigenetic marks potentially associated with COVID-19 development, clinical manifestation, and progression.

KW - ACE2

KW - COVID-19

KW - SARS-CoV-2

KW - TMPRSS2

KW - cytokine storm

KW - epigenetics

KW - multi-organ

KW - pro-inflammatory cytokines

UR - https://www.scopus.com/pages/publications/85117787726

U2 - 10.3389/fimmu.2021.752380

DO - 10.3389/fimmu.2021.752380

M3 - 文献综述

C2 - 34691068

AN - SCOPUS:85117787726

SN - 1664-3224

VL - 12

JO - Frontiers in Immunology

JF - Frontiers in Immunology

M1 - 752380

ER -

COVID-19 Is a Multi-Organ Aggressor: Epigenetic and Clinical Marks

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this